What is Rejoni?
Founded in 2020, Rejoni, Inc. operates at the intersection of material science and women's health. The company specializes in the development and commercialization of advanced gynecological products, utilizing proprietary biomaterials designed to address significant unmet clinical needs. By focusing on high-impact therapeutic areas, Rejoni has established a unique market position, bridging the gap between innovative laboratory research and practical, patient-centered medical applications. Its operational model is built upon a foundation of rigorous scientific validation and strategic partnerships with leading healthcare systems and venture capital entities.
How much funding has Rejoni raised?
Rejoni has raised a total of $65M across 3 funding rounds:
Series A
$15M
Series B
$25M
Other Financing Round
$25M
Series A (2020): $15M with participation from Delos Capital, Sparta Group, and Ascension Ventures
Series B (2022): $25M led by Iyengar Capital Partners, Amed Ventures, Sparta Group, Catalyst Health Ventures, Delos Capital, and Ascension
Other Financing Round (2026): $25M supported by Catalyst Health Ventures, Sparta Group, Ascension Ventures, Iyengar Capital Partners, Amed Ventures, Delos Capital, ClavystBio, and FemHealth Ventures
Key Investors in Rejoni
Catalyst Health Ventures
Catalyst Health Ventures is a venture capital firm focused on investing in transformative medical technologies that address global unmet healthcare needs, providing both capital and strategic mentorship.
Ascension Ventures
Ascension Ventures is a strategic healthcare venture firm that invests on behalf of leading community health systems to support companies transforming the healthcare industry.
Delos Capital
Delos Capital is a private equity firm specializing in complex transactions and financial advisory services, aiming to maximize alignment and outcomes through strategic involvement.
What's next for Rejoni?
With the successful closure of this major strategic investment, Rejoni is poised to accelerate its clinical pipeline and expand its commercial footprint. The company's strategic roadmap likely involves scaling manufacturing capabilities for its proprietary biomaterials and intensifying efforts toward regulatory approval for its core product suite. Furthermore, the continued support from institutional investors such as Catalyst Health Ventures and Ascension Ventures suggests a focus on long-term value creation through collaborative healthcare integration. As Rejoni moves forward, the emphasis will remain on optimizing patient outcomes while maintaining the operational agility required to disrupt the traditional gynecological care landscape.
See full Rejoni company page
